PFIZER REPORTS FOURTH-QUARTER AND FULL-YEAR 2015 RESULTS
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/11/2026
- Wall Street ends down as US-Iran peace optimism fades
- S&P 500 EPS growth above 20% is rare. Why 2027 may be at risk
- Goldman Sachs warns AI investment may be crowding out other business spending
- Why Wednesday's inflation print could provide the next dovish catalyst
- Tesla needs Robotaxi flywheel proof to boost investor conviction: Morgan Stanley
- After-Hours Movers: CRWV, NBIS, SMCI, LITE, CAVA, HRB
- After-Hours Movers: P, RIOT, BW, RKLB, HIMS, UPWK
- After-Hours Movers: TEAM, NET, TWLO, DOCS, FROG, DV, TTD, ABNB, DKNG, SG, RKT
- After-Hours Stock Movers: WDC, SNDK, FIG, APP, HUBS, SOUN, DASH, XYZ, Z, FLNC
- After-Hours Movers: SPCX, AMD, ANET, PINS, APPS, UPST, ZETA, BKNG, LCID, CPNG, MTCH
BMO Capital Reiterates Outperform on Pfizer (PFE) Following 4Q
February 3, 2016 8:21 AM ESTBMO Capital maintained an Outperform rating on Pfizer (NYSE: PFE), and cut the price target to $39.00 (from $41.00), following the company's 4Q earnings report. Good operational revenue growth drove a 3% top-line beat. The company's better-than-expected gross margin was offset by higher opex, but the lower tax rate helped drive the bottom-line penny beat. 2016 forecasts are below consensus, but BMO believes that the Street estimates will likely come down soon.
Analyst... More
